Other relevant cancer genes that were mutated in only one sample included ATR, ATX, BRCA2, CDH1, GATA3, PAX7, PIK3CA and ESR1. Thirty percent of the mutated driving genes were druggable with 91 anti-neo-neoplastic agents, of which 18 are drugs approved by the Food and Drug Administration (FDA) (S12 Table). The gene discussed is ESR1; the disease is cancer.